Cargando…

MON-467 Expression of Somatostatin Receptors in Aggressive Non-Functioning Pituitary Adenomas

INTRODUCTION Non-functioning pituitary adenomas (NFPAs) are usually benign. However, a substantial proportion of pituitary adenomas show an aggressive behavior with local invasion and increased risk of regrowth or recurrence after surgery. The treatment of choice for these adenomas is transsphenoida...

Descripción completa

Detalles Bibliográficos
Autores principales:	Soto, Alfonso, Venegas-Moreno, Eva, Gros Herguido, Noelia, Dios, Elena, Flores-Martínez, Alvaro, Madrazo-Atutxa, Ainara, Cardenas, Eugenio, Kaen, Ariel, Roldan, Florinda, Luque, Raul, Castano, Justo, Cano, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Neuroendocrinology and Pituitary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6551042/ http://dx.doi.org/10.1210/js.2019-MON-467

Ejemplares similares

Markers of Aggressiveness in Craniopharyngiomas
por: Del Can-Sanchez, Diego Jesús, et al.
Publicado: (2021)

Quantitative Analysis of Somatostatin and Dopamine Receptors Gene Expression Levels in Non-functioning Pituitary Tumors and Association with Clinical and Molecular Aggressiveness Features
por: Flores-Martinez, Álvaro, et al.
Publicado: (2020)

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2017)

MON-288 TSH Deficiency in Patients on Somatostatin Analog for TSH-PitNET
por: Illouz, Frederic, et al.
Publicado: (2020)

MON-LB081 Pituitary Adenomas: A Pan-genomic Classification
por: NEOU, Mario, et al.
Publicado: (2019)

MON-426 Non Functioning Pituitary Adenoma And Schizophrenia: An Incidental Association?
por: Shaamile, Ferrah, et al.
Publicado: (2019)

MON-459 ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, Attenuates GH Hypersecretion in Human GH-Secreting, Pituitary Adenoma-Derived Cells
por: Zhou, Cuiqi, et al.
Publicado: (2019)

MON-299 Risk Factors of Re-Growth of Non-Functional Pituitary Adenomas
por: Khalimova, Zamira Yusufovna, et al.
Publicado: (2020)

MON-255 Oral Contraceptive Pills Mask an Aggressive Crooke’s Cell Pituitary Adenoma
por: Gnanapragasam, Helen Prathiba, et al.
Publicado: (2020)

MON-269 FGFR-4 Expression in Pituitary Adenomas Is Associated with Aggressive Tumor Features
por: Kadioglu, Pinar, et al.
Publicado: (2020)

MON-LB50 Poor Response to Pre-Surgical Treatment With Somatostatin Receptor Ligands Is Associated With Diabetes Mellitus in Patients With Acromegaly
por: Frara, Stefano, et al.
Publicado: (2020)

MON-311 Glucose Metabolism in Acromegaly Patients Resistant to First Generation Somatostatin Receptor Ligands Treated with Pegvisomant And/Or Pasireotide Lar
por: Chiloiro, Sabrina, et al.
Publicado: (2020)

SAT-467 Gigantism Caused by Growth Hormone-Secreting Pituitary Macroadenoma: A Case Report
por: Tham, Ye Ni, et al.
Publicado: (2019)

MON-462 Cytokine Network in Pituitary Adenomas and Its Role in the Tumor Microenvironment: Focus on Macrophages
por: Marques, Pedro, et al.
Publicado: (2019)

MON-LB082 Elevated Expression of KISSR Is Associated with Secretory Function of Functioning Gonadotroph Adenomas
por: Wang, Linjie, et al.
Publicado: (2019)

MON-263 Renal Cell Cancer Metastasis to the Pituitary Masquerading as a Non-Functioning Adenoma
por: Vedere, Tarunya, et al.
Publicado: (2020)

MON-309 Prevalence of Silent Corticotroph Adenomas in a Large Cohort of Nonfunctioning Pituitary Adenomas: Plasma Proopiomelanocortin(POMC) Levels and Response to Pasireotide LAR
por: Reyes-Vidal, Carlos, et al.
Publicado: (2020)

MON-303 Giant Growth Hormone Secreting Pituitary Adenomas: A Single Institution Case Series
por: Koylu, Bahadir, et al.
Publicado: (2020)

MON-440 Cyberknife Radiosurgery for Functional and Non-Functional Pituitary Adenomas: Long-Term Single-Center Experience
por: Yuen, Kevin, et al.
Publicado: (2019)

MON-326 Non Functioning Pituitary Adenomas (NFPA): Sex Related Differences in Presentation, Clinical Features and Outcomes
por: Rosmino, Josefina, et al.
Publicado: (2020)

MON-477 Octreotide and ONO-ST-468, a Novel and Potent Somatostatin Receptor Type-2 (SST2) Agonist, Suppress GH Hypersecretion in the Monkey
por: Tanaka, Hirotaka, et al.
Publicado: (2019)

MON-324 Management and Therapeutic Response Comparison in Prolactinomas According to Tumor Size
por: Flores-Cardenas, Romina
Publicado: (2020)

OR06-02 TBR-760, a Chimeric Somatostatin-Dopamine Compound, Arrests Aggressive Non-Functioning Pituitary Adenoma Growth In Vivo
por: Halem, Heather A, et al.
Publicado: (2020)

MON-320 Inter-Rater Reliability of T2 MRI Intensity of Somatotroph Adenomas; Endocrinologists vs. Neuroradiologist Pilot Study
por: Varlamov, Elena V, et al.
Publicado: (2020)

MON-295 Desmopressin Test in Silent Corticothoph Pituitary Adenomas, a Preliminary Study - a Comparison with Cushing Disease
por: Huayllas, Martha Katherine, et al.
Publicado: (2020)

MON-469 Pituitary Corticotroph Lesions: Clinical, Biochemical, and Pathological Characterization of Cushing Disease, Silent Corticotroph Adenomas, and Corticotroph Hyperplasia
por: Castlen, Joseph, et al.
Publicado: (2019)

MON-304 Prolactin as a Surrogate Marker to Predict Long Term Postoperative Hypopituitarism After Transsphenoidal Resection of Pituitary Adenomas
por: German, Massiell, et al.
Publicado: (2020)

MON-464 Non-Clinical Profiling of ONO-5788, a Novel Oral Small Molecule Somatostatin Receptor Type-2 (SST2) Agonist, to Support Studies in Humans
por: Komagata, Tatsuya, et al.
Publicado: (2019)

MON-LB53 Prior Injectable Somatostatin Receptor Ligand Dose Does Not Predict Oral Octreotide Response In The Treatment Of Acromegaly: Results From The Phase 3 OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

RF01 | PMON168 Hedgehog-Induced Somatostatin Receptor Expression is Inhibited by the Activation of the Glucocorticoid Receptor Signaling Pathway in Human Pituitary Adenoma Organoids
por: Zavros, Yana, et al.
Publicado: (2022)

SUN-467 Vitamin B(6) and N-Acetylcysteine Protect Hypothalamic Neurons from Bisphenol A-Mediated Induction of Neuropeptide Y Gene Expression
por: Loganathan, Neruja, et al.
Publicado: (2019)

MON-297 Withdrawal from Long-Acting Somatostatin Receptor Ligand Injections in Adult Patients with Acromegaly: Results from the Phase 3, Randomized, Double-Blind, Placebo-Controlled CHIASMA OPTIMAL Study
por: Nachtigall, Lisa B, et al.
Publicado: (2020)

MON-323 IGF-I Variability and Its Association with Demographic and Clinical Characteristics in Patients with Acromegaly Treated with Injectable Somatostatin Receptor Ligands (SRLS); Results from an International Prospective Phase III Study
por: Samson, Susan Leanne, et al.
Publicado: (2020)

MON-460 Pasireotide Treatment Inhibits Cytokine Release from Pituitary Adenoma-Associated Fibroblasts: Is This Mechanism Playing a Key Role in Its Effect?
por: Marques, Pedro, et al.
Publicado: (2019)

MON-430 To B, or Not to B
por: Pradeep, Pallavi, et al.
Publicado: (2019)

FRI296 Somatostatin Receptor 5 Staining In Prolactinomas
por: Mehta, Sonal, et al.
Publicado: (2023)

THU063 Somatostatin Analog Neoadjuvant Treatment Before Endoscopic Surgery For Growth-Hormone Producing Pituitary Adenomas Invading The Cavernous Sinus: Case Series, Systematic Literature Review And Meta-analysis
por: Rapoport, Benjamin, et al.
Publicado: (2023)

MON-LB46 Thyrotropinoma and Pregnancy
por: Namboodiri, Divya, et al.
Publicado: (2020)

MON-317 Prognostic Factors and Mortality According to the Structural and Functional Classification of Acromegaly
por: Haro, Andrea Rocha, et al.
Publicado: (2020)

MON-LB55 Biochemical Control of Most Patients Reverting to Injectable Long-Acting Somatostatin Receptor Ligands Is Achieved After One Dose: Results From the Phase 3, Randomized, Double Blind, Placebo-Controlled Optimal Study
por: Fleseriu, Maria, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_r8r0q932oirdjjnfufdhc35qgh